Source - Alliance News

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC’s savolitinib in combination with Astra’s osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

The results show a trend toward improved response rates with an increasing level of mesenchymal epithelial transition receptor-driven tumours. Across all patients, the objective response rate was 32%, with a median duration of response at 8.3 months and a median progressing-free survival of 5.3 months.

The findings from the ongoing Savannah study supports the start of the Saffron phase three study in patients with EGFR-mutated, MET-driven NSCLC.

Current stock price: 219.74 pence, down 5.8% on Wednesday

12-month change: down 59%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Hutchmed (China) Limited (HCM)

+0.55p (+0.21%)
delayed 15:33PM

Astrazeneca PLC (AZN)

-26.00p (-0.24%)
delayed 15:34PM